Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Cervical Cancer | Research article

CRKL regulates alternative splicing of cancer-related genes in cervical cancer samples and HeLa cell

Authors: Qingling Song, Fengtao Yi, Yuhong Zhang, Daniel K. Jun Li, Yaxun Wei, Han Yu, Yi Zhang

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Aberrant spliced isoforms are specifically associated with cancer progression and metastasis. The cytoplasmic adaptor CRKL (v-crk avian sarcoma virus CT10 oncogene homolog-like) is a CRK like proto-oncogene, which encodes a SH2 and SH3 (src homology) domain-containing adaptor protein. CRKL is tightly linked to leukemia via its binding partners BCR-ABL and TEL-ABL, upregulated in multiple types of human cancers, and induce cancer cell proliferation and invasion. However, it remains unclear whether signaling adaptors such as CRKL could regulate alternative splicing.

Methods

We analyzed the expression level of CRKL in 305 cervical cancer tissue samples available in TCGA database, and then selected two groups of cancer samples with CRKL differentially expressed to analyzed potential CRKL-regulated alternative splicing events (ASEs). CRKL was knocked down by shRNA to further study CRKL-regulated alternative splicing and the activity of SR protein kinases in HeLa cells using RNA-Seq and Western blot techniques. We validated 43 CRKL-regulated ASEs detected by RNA-seq in HeLa cells, using RT-qPCR analysis of HeLa cell samples and using RNA-seq data of the two group of clinical cervical samples.

Results

The expression of CRKL was mostly up-regulated in stage I cervical cancer samples. Knock-down of CRKL led to a reduced cell proliferation. CRKL-regulated alternative splicing of a large number of genes were enriched in cancer-related functional pathways, among which DNA repair and G2/M mitotic cell cycle, GnRH signaling were shared among the top 10 enriched GO terms and KEGG pathways by results from clinical samples and HeLa cell model. We showed that CRKL-regulated ASEs revealed by computational analysis using ABLas software in HeLa cell were highly validated by RT-qPCR, and also validated by cervical cancer clinical samples.

Conclusions

This is the first report of CRKL-regulation of the alternative splicing of a number of genes critical in tumorigenesis and cancer progression, which is consistent with CRKL reported role as a signaling adaptor and a kinase. Our results underline that the signaling adaptor CRKL might integrate the external and intrinsic cellular signals and coordinate the dynamic activation of cellular signaling pathways including alternative splicing regulation.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef
2.
Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet. 2007;370(9585):398–406.PubMedCrossRef
3.
Sankaranarayanan R. HPV vaccination: the promise & problems. Indian J Med Res. 2009;130(3):322–6.PubMed
4.
Ronco G, Giorgirossi P, Carozzi F, Confortini M, Palma PD, Mistro AD, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249–57.PubMedCrossRef
5.
Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524–32.PubMedCrossRef
6.
Sankaranarayanan R, D M, Nene BM, D M, RCP F, Shastri SS, et al. HPV screening for cervical Cancer in rural India. N Engl J Med. 2009;361(3):305 author reply 6.
7.
Angioli R, Plotti F, Luvero D, Aloisi A, Guzzo F, Capriglione S, et al. Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study. Tumor Biol. 2014;35(3):2741–6.CrossRef
8.
Organista-Nava J, Gómez-Gómez Y, Gariglio P. Embryonic stem cell-specific signature in cervical cancer. Tumour Biol. 2014;35(3):1727–38.PubMedCrossRef
9.
Du PL, Wu KS, Fang JY, Zeng Y, Xu ZX, Tang WR, et al. Cervical Cancer mortality trends in China, 1991-2013, and predictions for the future. Asian Pac J Cancer Prev. 2015;16(15):6391.PubMedCrossRef
10.
Modrek B, Lee C. A genomic view of alternative splicing. Nat Genet. 2001;30(1):13–9.CrossRef
11.
Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem. 2003;72(1):291–336.PubMedCrossRef
12.
Matlin AJ, Clark F, Smith CW. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol. 2005;6(6):386–98.PubMedCrossRef
13.
Sultan M, Schulz MH, Richard H, Magen A, Klingenhoff A, Scherf M, et al. A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science. 2008;321(5891):956–60.PubMedCrossRef
14.
15.
Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008;40(12):1413–5.PubMedCrossRef
16.
17.
Ghigna C, Valacca C, & Biamonti G. Alternative splicing and tumor progression. Current genomics. 2008;9(8):556–570.
18.
Venables JP, Klinck R, Koh C, Gervaisbird J, Bramard A, Inkel L, et al. Cancer-associated regulation of alternative splicing. Nat Struct Mol Biol. 2009;16(6):670–6.PubMedCrossRef
19.
20.
21.
Chen J, Weiss WA. Alternative splicing in cancer: implications for biology and therapy. Oncogene. 2015;34(1):1–14.PubMedCrossRef
22.
Liu F, Dai M, Xu Q, Zhu X, Zhou Y, Jiang S, et al. SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-κB-CD47 axis. Oncogene. 2018;37(3).PubMedPubMedCentralCrossRef
23.
Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol. 2002;29((1 Suppl 4)):47.PubMedCrossRef
24.
Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res. 2003;284(1):122–30.PubMedCrossRef
25.
Coxon A, Rozenblum E, Park YS, Joshi N, Tsurutani J, Dennis PA, et al. Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes. Cancer Res. 2005;65(16):7137–44.PubMedCrossRef
26.
Schwarz JK, Payton JE, Rashmi R, Xiang T, Jia Y, Huettner P, et al. Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical Cancer. Clin Cancer Res. 2012;18(5):1464–71.PubMedPubMedCentralCrossRef
27.
Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97(9):643.PubMedCrossRef
28.
Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–81.PubMedCrossRef
29.
Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non–small-cell lung Cancer. J Clin Oncol. 2007;25(5):587–95.PubMedCrossRef
30.
Koch CA, Anderson D, Moran MF, Ellis C, Pawson T. SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science. 1991;252(5006):668–74.PubMedCrossRef
31.
Rozakisadcock M, Fernley R, Wade J, Pawson T, Bowtell D. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature. 1993;363(6424):83.CrossRef
32.
Ten HJ, Morris C, Heisterkamp N, Groffen J. Isolation and chromosomal localization of CRKL, a human crk-like gene. Oncogene. 1993;8(9):2469–74.
33.
Feller SM. Crk family adaptors–signalling complex formation and biological roles. Oncogene. 2001;20(44):6348–71.PubMedCrossRef
34.
Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ, Jackson SP. MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell. 2005;123(7):1213.PubMedCrossRef
35.
Slagsvold T, Pattni K, Malerød L, Stenmark H. Endosomal and non-endosomal functions of ESCRT proteins. Trends Cell Biol. 2006;16(6):317–26.PubMedCrossRef
36.
Raiborg C, Wesche J, Malerød L, Stenmark H. Flat clathrin coats on endosomes mediate degradative protein sorting by scaffolding Hrs in dynamic microdomains. J Cell Sci. 2006;119(Pt 12:2414–24.PubMedCrossRef
37.
Teo H, Gill DJ, Sun J, Perisic O, Veprintsev DB, Vallis Y, et al. ESCRT-I core and ESCRT-II GLUE domain structures reveal role for GLUE in linking to ESCRT-I and membranes. Cell. 2006;125(1):99.PubMedCrossRef
38.
Pawson T. Dynamic control of signaling by modular adaptor proteins. Curr Opin Cell Biol. 2007;19(2):112–6.PubMedCrossRef
39.
Ren R, Ye ZS, Baltimore D. Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites. Genes Dev. 1994;8(7):783.PubMedCrossRef
40.
Sakai R, Iwamatsu A, Hirano N, Ogawa S, Tanaka T, Mano H, et al. A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. EMBO J. 1994;13(16):3748–56.PubMedPubMedCentralCrossRef
41.
De JR, Ten HJ, Heisterkamp N, Groffen J. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia. J Biol Chem. 1995;270(37):21468–71.CrossRef
42.
Salgia R, Uemura N, Okuda K, Li JL, Pisick E, Sattler M, et al. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem. 1995;270(49):29145–50.PubMedCrossRef
43.
Salgia R, Pisick E, Sattler M, Li JL, Uemura N, Wong WK, et al. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J Biol Chem. 1996;271(41):25198–203.PubMedCrossRef
44.
Ribon V, Hubbell S, Herrera R, Saltiel AR. The product of the cbl oncogene forms stable complexes in vivo with endogenous Crk in a tyrosine phosphorylation-dependent manner. Mol Cell Biol. 1996;16(1):45.PubMedPubMedCentralCrossRef
45.
Beitner-Johnson D, Blakesley VA, Shen-Orr Z, Jimenez M, Stannard B, Wang LM, et al. The proto-oncogene product c-Crk associates with insulin receptor substrate-1 and 4PS. Modulation by insulin growth factor-I (IGF) and enhanced IGF-I signaling. J Biol Chem. 1996;271(16):9287–90.PubMedCrossRef
46.
Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, et al. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene. 1996;12(4):839–46.PubMed
47.
Sattler M, Salgia R, Shrikhande G, Verma S, Uemura N, Law SF, et al. Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1). J Biol Chem. 1997;272(22):14320–6.PubMedCrossRef
48.
Sattler M, Salgia R, Shrikhande G, Verma S, Pisick E, Prasad KV, et al. Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL). J Biol Chem. 1997;272(15):10248.PubMedCrossRef
49.
Gesbert F, Garbay C, Bertoglio J. Interleukin-2 stimulation induces tyrosine phosphorylation of p120-Cbl and CrkL and formation of multimolecular signaling complexes in T lymphocytes and natural killer cells. J Biol Chem. 1998;273(7):3986–93.PubMedCrossRef
50.
Koval AP, Karas M, Zick Y, Leroith D. Interplay of the proto-oncogene proteins CrkL and CrkII in insulin-like growth factor-I receptor-mediated signal transduction. J Biol Chem. 1998;273(24):14780.PubMedCrossRef
51.
Fish EN, Uddin S, Korkmaz M, Majchrzak B, Druker BJ, Platanias LC. Activation of a CrkL-stat5 signaling complex by type I interferons. J Biol Chem. 1999;274(2):571.PubMedCrossRef
52.
Akagi T, Shishido T, Murata K, Hanafusa H. V-Crk activates the phosphoinositide 3-kinase/AKT pathway in transformation. Proc Natl Acad Sci U S A. 2000;97(13):7290–5.PubMedPubMedCentralCrossRef
53.
Birge RB, Kalodimos C, Inagaki F, Tanaka S. Crk and CrkL adaptor proteins: networks for physiological and pathological signaling. Cell Commun Signal. 2009;7(1):13.PubMedPubMedCentralCrossRef
54.
Mayer BJ, Gupta R. Functions of SH2 and SH3 domains. Curr Top Microbiol Immunol. 1998;228(228):1.PubMed
55.
Larsson H, Klint P, Landgren E, Claesson-Welsh L. Fibroblast growth factor receptor-1-mediated endothelial cell proliferation is dependent on the Src homology (SH) 2/SH3 domain-containing adaptor protein Crk. J Biol Chem. 1999;274(36):25726–34.PubMedCrossRef
56.
Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci. 2001;22(4):201–7.PubMedCrossRef
57.
Salameh A, Galvagni F, Bardelli M, Bussolino F, Oliviero S. Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood. 2005;106(10):3423.PubMedCrossRef
58.
Moon AM, Guris DL, Seo J, Li L, Hammond J, Talbot A, et al. Crkl deficiency disrupts Fgf8 signaling in a mouse model of 22q11 deletion syndromes. Dev Cell. 2006;10(1):71.PubMedPubMedCentralCrossRef
59.
Cheung HW, Du J, Boehm JS, He F, Weir BA, Wang X, et al. Amplification of CRKL induces transformation and EGFR inhibitor resistance in human non small cell lung cancers. Cancer Discov. 2011;1(7):608–25.PubMedPubMedCentralCrossRef
60.
Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem. 1994;269(37):22925–8.PubMed
61.
Senechal K, Halpern J, Sawyers CL. The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene. J Biol Chem. 1996;271(38):23255–61.PubMedCrossRef
62.
Posern G. The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways. Oncogene. 2000;19(13):1684–90.PubMedCrossRef
63.
Rhodes J, York RD, Tara D, Tajinda K, Druker BJ. CrkL functions as a nuclear adaptor and transcriptional activator in Bcr-Abl–expressing cells. Exp Hematol. 2000;28(3):305–10.PubMedCrossRef
64.
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899.PubMedPubMedCentralCrossRef
65.
Kim YH, Kwei KA, Luc G, Keyan S, Jessica K, Manuela PG, et al. Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer. Oncogene. 2010;29(10):1421–30.PubMedCrossRef
66.
Wang J, Chen X, Li P, Su L, Yu B, Cai Q, et al. CRKL promotes cell proliferation in gastric cancer and is negatively regulated by miR-126. Chem Biol Interact. 2013;206(2):230–8.PubMedCrossRef
67.
Zhao T, Miao Z, Wang Z, Xu Y, Wu J, Liu X, et al. Overexpression of CRKL correlates with malignant cell proliferation in breast cancer. Tumour Biol. 2013;34(5):2891–7.PubMedCrossRef
68.
Ji H, Li B, Zhang S, He Z, Zhou Y, Ouyang L. Crk-like adapter protein is overexpressed in cervical carcinoma, facilitates proliferation, invasion and chemoresistance, and regulates Src and Akt signaling. Oncol Lett. 2016;12(5):3811–7.PubMedPubMedCentralCrossRef
69.
Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med. 1996;74(10):589.PubMedCrossRef
70.
Colwill K, Pawson T, Andrews B, Prasad J, Manley JL, Bell JC, et al. The Clk/sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. EMBO J. 1996;15(2):265–75.PubMedPubMedCentralCrossRef
71.
Duncan PI, Stojdl DF, Marius RM, Bell JC. In vivo regulation of alternative pre-mRNA splicing by the Clk1 protein kinase. Mol Cell Biol. 1997;17(10):5996–6001.PubMedPubMedCentralCrossRef
72.
Patel NA, Kaneko S, Apostolatos HS, Sun SB, Watson JE, Davidowitz K, et al. Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase CβII alternative splicing via phosphorylation of serine/arginine-rich splicing factor SRp40. J Biol Chem. 2005;280(14):14302–9.PubMedCrossRef
73.
Shi J, Qian W, Yin X, Iqbal K, Grundkeiqbal I, Gu X, et al. Cyclic AMP-dependent protein kinase regulates the alternative splicing of TAU exon 10: A MECHANISM INVOLVED IN TAU PATHOLOGY OF ALZHEIMER DISEASE. J Biol Chem. 2011;286(16):14639–48.PubMedPubMedCentralCrossRef
74.
Zhou Z, Qiu J, Liu W, Zhou Y, Plocinik RM, Li H, et al. The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. Mol Cell. 2012;47(3):422–33.PubMedPubMedCentralCrossRef
75.
Castello A, Fischer B, Eichelbaum K, Horos R, Beckmann BM, Strein C, et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell. 2012;149(6):1393–406.PubMedCrossRef
76.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–8.PubMedCrossRef
77.
Li RZ, Hou J, Wei Y, Luo X Ye, Y & Zhang Y. hnRNPDL extensively regulates transcription and alternative splicing. Gene. 2019;687:125–134.
78.
Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14(4):R36.PubMedPubMedCentralCrossRef
79.
Robinson MD, Mccarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139.PubMedCrossRef
80.
Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S, et al. KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res. 2011;39(Web Server issue:316–22.CrossRef
81.
Xia H, Chen D, Wu Q, Wu G, Zhou Y, Zhang Y, & Zhang L. CELF1 preferentially binds to exon-intron boundary and regulates alternative splicing in HeLa cells. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms. 2017;1860(9):911–21.
82.
Jin L, Li G, Yu D, Wei H, Chao C, Liao S, et al. Transcriptome analysis reveals the complexity of alternative splicing regulation in the fungus Verticillium dahliae. BMC Genomics. 2017;18(1):130.PubMedPubMedCentralCrossRef
83.
Pertea G. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28(5):511–5.PubMedPubMedCentralCrossRef
84.
85.
Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, & Greenberg ME. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 1997;275(5300):661–65.
86.
Blaustein M, Pelisch F, Tanos T, Muñoz MJ, Wengier D, Quadrana L, et al. Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT. Nat Struct Mol Biol. 2005;12(12):1037–44.PubMedCrossRef
87.
Fu L, Dong Q, Xie C, Wang Y, Li Q. CRKL protein overexpression enhances cell proliferation and invasion in pancreatic cancer. Tumor Biol. 2015;36(2):1015–22.CrossRef
88.
Barber MA, Welch HC. PI3K and RAC signalling in leukocyte and cancer cell migration. Bull Cancer. 2006;93(5):E44.PubMed
89.
Hwang SL, Chang JH, Cheng TS, Sy WD, Lieu AS, Lin CL, et al. Expression of Rac3 in human brain tumors. J Clin Neurosci. 2005;12(5):571–4.PubMedCrossRef
90.
Wang G, Wang H, Zhang C, Liu T, Li Q, Lin X, et al. Rac3 regulates cell proliferation through cell cycle pathway and predicts prognosis in lung adenocarcinoma. Tumor Biol. 2016;37(9):1–11.CrossRef
91.
Donnelly SK, Cabrera R, Mao S, Christin JR, Wu B, Guo W, et al. Rac3 regulates breast cancer invasion and metastasis by controlling adhesion and matrix degradation. J Cell Biol. 2017;216(12):jcb.201704048.CrossRef
92.
Xu AL, Yu GQ, Kong XC, Qiu XH, Li PL. Effect of Rac1 downregulation mediated by shRNA on the biological behaviour of human cervical cancer cells. J Int Med Res. 2013;41(4):1037.PubMedCrossRef
93.
Kawasaki Y, Senda T, Ishidate T, Koyama R, Morishita T, Iwayama Y, et al. Asef, a link between the tumor suppressor APC and G-protein signaling. Science. 2000;289(5482):1194–7.PubMedCrossRef
94.
Zhan L, Rosenberg A, Bergami KC, Yu M, Xuan Z, Jaffe AB, et al. Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell. 2008;135(5):865–78.PubMedPubMedCentralCrossRef
95.
Lev S, Moreno H, Martinez R, Canoll P, Peles E, Musacchio JM, et al. Protein tyrosine kinase PYK2 involved in ca (2+)-induced regulation of ion channel and MAP kinase functions. Nature. 1995;376(6543):737.PubMedCrossRef
96.
Chen YF, Chiu WT, Chen YT, Lin PY, Huang HJ, Chou CY, et al. Calcium store sensor stromal-interaction molecule 1-dependent signaling plays an important role in cervical cancer growth, migration, and angiogenesis. Proc Natl Acad Sci U S A. 2011;108(37):15225–30.PubMedPubMedCentralCrossRef
97.
M B, S V, N M, R D, H C, E W, et al. Substrate specificity and activity regulation of protein kinase MELK. J Biol Chem. 2005;280(48):40003–11.CrossRef
98.
Lin ML, Park JH, Nishidate T, Nakamura Y, Katagiri T. Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family. Breast Cancer Res. 2007;9(1):1–13.CrossRef
99.
Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A. 2002;99(21):13571–6.PubMedPubMedCentralCrossRef
100.
A A, J Z, S B, I L, D O, NM D, et al. Requirement of protein phosphatase 5 in DNA-damage-induced ATM activation. Genes Dev. 2004;18(3):249.CrossRef
101.
Kastan MB, Lim D. The many substrates and functions of ATM. Nat Rev Mol Cell Biol. 2000;1(3):179–86.PubMedCrossRef
102.
Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer. 2003;3(3):155–68.CrossRefPubMed
103.
Boise LH, Gonzálezgarcía M, Postema CE, Ding L, Lindsten T, Turka LA, et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993;74(4):597–608.PubMedCrossRef
Metadata
Title
CRKL regulates alternative splicing of cancer-related genes in cervical cancer samples and HeLa cell
Authors
Qingling Song
Fengtao Yi
Yuhong Zhang
Daniel K. Jun Li
Yaxun Wei
Han Yu
Yi Zhang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5671-8

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Research article

The prognostic association of SPAG5 gene expression in breast cancer patients with systematic therapy

Case report

Identification of a metastatic lung adenocarcinoma of the palate mucosa through genetic and histopathological analysis: a rare case report and literature review

Research article

Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer

Research article

Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer

Case report

Sinonasal desmoplastic small round cell tumor: a case report and review of the literature

Study protocol

First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits